About Enhancer
| Enhancer ID: | E_02019 |
| Species: | Homo sapiens |
| Position : | chr13:28268000-28270000   |
| Year: | 2022 |
| Title: | Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | B-cell acute lymphoblastic leukemia |
| PMID: | 35316324 |
| MONDO: | MONDO:0004947 |
| Tissue: | bone marrow |
| Tissue Ontology ID: | UBERON:0002371 |
| Cell Source: | NALM-16 |
| CVCL ID: | CVCL_1834 |
| Cell Type: | B-lymphoblast |
| Cell Ontology ID: | CL:0017006 |
| Experiment Type: | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation |
| High Throughput Method: | ChIP-seq; ATAC-seq; 4C-seq; RNA-seq |
| Low Throughput Method: | CRISPR interference; RT-qPCR; Western blot; CRISPRi; 4C |
About Target Gene
| Target gene : | CDX2 |
About TF
| TF name : | NA |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|
Enhancer Associated Network
Overlapping Enhancers (hg19)
No overlapping enhancers found in hg19 at this locus.
Expression of Target Genes for the Enhancer